12,896 Shares in Pfizer Inc. (NYSE:PFE) Acquired by Aegis Wealth Management LLC

Aegis Wealth Management LLC acquired a new stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The fund acquired 12,896 shares of the biopharmaceutical company's stock, valued at approximately $342,000.

Other hedge funds have also modified their holdings of the company. Norges Bank purchased a new stake in Pfizer in the 4th quarter worth $2,328,986,000. Charles Schwab Investment Management Inc. boosted its stake in shares of Pfizer by 19.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company's stock worth $4,124,330,000 after acquiring an additional 25,315,159 shares during the period. Starboard Value LP purchased a new stake in shares of Pfizer during the fourth quarter worth about $407,730,000. Raymond James Financial Inc. bought a new stake in Pfizer during the 4th quarter valued at approximately $274,694,000. Finally, Massachusetts Financial Services Co. MA raised its stake in Pfizer by 7.5% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company's stock valued at $2,029,604,000 after purchasing an additional 5,350,381 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on PFE shares. Citigroup restated a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. Cantor Fitzgerald initiated coverage on shares of Pfizer in a report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price target on the stock. The Goldman Sachs Group reissued a "neutral" rating and issued a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Finally, Guggenheim reiterated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, four have given a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $29.17.

Pfizer Stock Up 0.0%

NYSE PFE traded up $0.01 during trading on Friday, reaching $23.46. 56,576,195 shares of the company's stock traded hands, compared to its average volume of 41,238,850. The company's 50 day simple moving average is $23.12 and its two-hundred day simple moving average is $25.07. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The firm has a market cap of $133.38 billion, a price-to-earnings ratio of 16.64, a price-to-earnings-growth ratio of 0.64 and a beta of 0.58. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. During the same quarter in the previous year, the firm earned $0.82 EPS. The company's quarterly revenue was down 7.8% compared to the same quarter last year. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.33%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer's dividend payout ratio (DPR) is presently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.